ABOUT

TEAM

Leadership Profiles

Tetra Bio-Pharma’s executive team, board of directors, and advisory committee are recognized experts in their respective fields including drug development, regulatory affairs, clinical research, intellectual property, marketing and medical affairs.

Together, the company’s leadership team provides an extensive background to support Tetra Bio-Pharma’s long-term vision to offer a diverse portfolio of cannabinoid-derived drugs to address unmet medical needs.

EXECUTIVE MANAGEMENT TEAM

Dr. Guy Chamberland, M.Sc., Ph.D., Master Herbalist, has served as Tetra Bio-Pharma’s Chief Executive Officer and Chief Scientific Officer since October 15, 2018. He held the positions of Interim Chief Executive Officer and Chief Scientific Officer respectively since April 2018 and June 2016. Dr. Chamberland’s extensive experience in both executive and scientific roles establish him as an expert in the biopharmaceutical space. Dr. Chamberland has more than two decades of experience in drug development for the North American pharmaceutical industry with specific expertise in regulatory affairs, and the development and management of clinical research protocols and clinical studies for botanical medicines. He was also a member of the investment committee of the venture capital fund, Fonds Bionvation, for 7 years.

Dr. Chamberland has become a thought leader in botanical medicine, publishing, lecturing and delivering continuing education workshops to health professionals on the use of plants for the treatment of pain, anxiety, insomnia, and wound healing. He is a Professor of Botanical Medicine and Principles of Clinical Research at the École d’Enseignement Supérieur de Naturopathie du Québec (EESNQ) and the French language equivalent of the Canadian College of Naturopathic Medicine (CCNNM).  He earned a diploma in Proficiency in Herbal Prescription from the Australian College of Phytotherapy, and Certified Herbalist and Master Herbalist diplomas from the Dominion College of Canada. Dr. Chamberland received a B.Sc. in Agriculture form McGill University, an M.Sc. in Veterinary Anatomy and Physiology and a Ph.D. in Biomedical Sciences (toxicology) from the University of Montreal.

Mr. Di Paola has over a decade of experience in audit, finance and accounting as an auditor for PricewaterhouseCoopers and BDO Canada and has been involved with numerous financing and spin-out transactions. His specialization includes accounting for public and private companies as well as for not profit organizations. Sabino is a Chartered Public Accountant and holds a degree from Concordia University.

Mr. Néron has more than three decades of experience in the pharmaceutical industry where challenging the reimbursement landscape factored prominently in his role, with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada. Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market-leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).

Melanie Kelly is a Professor in Pharmacology and Ophtamology at Dalhousie University in Halifax with expertise in preclinical and clinical research design, novel drug development, medical cannabis and cannabinoid based drugs.

A respected research professional with a Doctor of Philosophy (PhD) focused on drug discovery and molecular pharmacology, Dr. Kelly has significant research experience in the field of G protein coupled receptors and endocannabinoid/cannabinoid signaling. She is considered to be an expert in the cannabinoid drug development space.

Her primary research expertise is pharmacology, specifically receptors and cell signaling pathways. Her work has examined pathways important to the survival of retinal ganglion cells in experimental models of glaucoma and has made us of gene mutations, to explore signaling pathways involved in retinal progenitor cell growth and development. Dr. Kelly’s current research addresses the pharmacology of the endocannabinoids and lipid signaling in the mammalian eye, with a specific focus on the regulation of intraocular pressure and interactions between glial cells and microvasculature in the regulation of retinal blood flow.

She is a member of the International Cannabis Research Society.

 

Dr. De Pauw is responsible for clinical operations and relations with the medical community with a view to building Tetra Bio-Pharma’s clinical department and ensuring it continues to meet the highest standards of a pharmaceutical company. She also directs the Company’s public education initiatives to build and increase awareness about the benefits and adverse effects of cannabis-cased treatment.

Aurelia holds a master’s degree and PhD in Science from the Gembloux Agro-Bio Tech, University of Liege and the University of Namur, Belgium. She followed this with a five-year post-doctoral position in the field of stem cell therapy. After establishing her career in basic sciences and regenerative therapy, she progressed from the laboratory bench to the bedside where she gained an even deeper appreciation of the impact of research on patients and caregivers. Aurelia has extensive experience in numerous therapeutic categories including oncology, drug abuse, endocrinology, dermatology and cardiology.

 

Mr. Yifrach-Stav has extensive experience in pharmaceutical and medical device industries where he worked with major medical device, pharmaceutical and cosmetic companies in North America, Europe and Asia.  During this time, he successfully lead the preparation of companies for Quality Audits by Health Canada, FDA, EU and Israeli Ministry of Health.  Over the years he developed expertise in production process validations and other areas of quality assurance. Ofer is responsible for the scale-up activities of our lead products  and ensuring our readiness for the submission of NDS/NDA.

Ofer holds a master’s degree in Environmental Engineering, graduated with honours, and a Bachelor’s degree in Biotechnology Engineering from Ben-Gurion University of the Negev, in Israel.

BOARD OF DIRECTORS

Dr. Cheliak is the CEO of Panag Pharma, a Canadian biotech company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Dr. Cheliak has over 20 years of business experience in a wide variety of biotechnology fields, including vaccines, human genetics, oncology, neurology and anti-infective drug development and CRO services. In addition to having held executive positions in the public sector, he has extensive deal-making experience within the pharmaceutical industry, academic institutions and research hospitals including securing financing with both big and small pharma. He currently serves as a Director of Solarvest (SVS) and is Vice Chair of the Government of Canada’s Networks Centres of Excellence (NCE) Standing Selection Committee and Chair of the NCE Monitoring Committee providing advice and recommendations to the Government of Canada on funding of large national science and infrastructure initiatives. Dr. Cheliak has a Ph.D. in Genetics from the University of Alberta.

Until 2013, Greg Drohan served as President of the Board of Church and Dwight Canada Corp. While there, Drohan successfully merged the Church & Dwight and Carter-Horner businesses which led to the doubling of sales revenue and achieved #1 market share on brands such as Trojans, Oxi Clean, First Response, Rub A535 and Arm & Hammer. Following his successful 40-year career in the consumer products sector Mr. Drohan has established a management consulting practice. In addition to his board role at Church and Dwight, he also served as Director of the Ryerson University Alumni Relations Board. Drohan holds an MBA from York University and a BBM from Ryerson Polytechnical Institute.

Mr. Merton has over 20 years of financial and business experience, including 10 years as CFO for public companies involved in the capital markets. Following 12 years with Ernst & Young and KPMG, he transitioned from the audit stream into financial advisory work, as a Business Valuator, Forensic Accountant and Corporate Finance specialist. After leaving KPMG, Mr. Merton joined Atlas Tube Inc., as Vice-President, Special Projects. Since assisting in the sale of Atlas Tube, Mr. Merton became the CFO of Reko International Group Inc. In December 2014, Mr. Merton was elected by shareholders as a member of the inaugural Board of Directors of Aphria Inc. Approximately one year later, Mr. Merton resigned as a member of the Board and joined Aphria as its CFO. In this role, Mr. Merton is responsible for communication with all stakeholders and is a member of the executive management team responsible for the strategic direction of Aphria, as well as leading all acquisition discussions, budgeting, financing, financial reporting and internal controls. Mr. Merton is a Chartered Professional Accountant, a Chartered Accountant and is a Fellow of the Canadian Institute of Chartered Business Valuators (the “CICBV”).

SCIENTIFIC ADVISORY BOARD

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur at ex mauris. Vestibulum vulputate condimentum purus id dapibus. Fusce elementum tempor augue, eget tincidunt tortor posuere id. Vestibulum eu diam egestas, aliquam eros ac, pellentesque arcu. Donec vel nibh non lorem semper elementum. Proin cursus, mi et sodales ornare, arcu tellus pellentesque mauris, ut tempus magna ligula malesuada metus. Proin eget malesuada est. Curabitur sit amet leo ac quam cursus aliquet. Nunc vitae porttitor nisi. Cras vitae nulla id augue efficitur interdum. Quisque tempus ligula quis nibh lobortis, eu maximus orci dictum. Nulla a diam eget ex vestibulum rhoncus.

Suspendisse feugiat neque sit amet faucibus facilisis. Praesent nec sapien id odio ultrices lacinia vel ut lectus. Sed scelerisque luctus nisi eu luctus. Quisque a lorem eget ipsum venenatis ultricies quis ut velit. Suspendisse et auctor tellus. Fusce mauris lectus, semper in nisl sit amet, fringilla mollis odio. Praesent rhoncus, dui eget sodales fringilla, lectus ligula accumsan mauris, a malesuada lectus enim non tortor. Curabitur tincidunt, lacus ac condimentum vulputate, libero est vulputate enim, consequat tincidunt risus nunc quis arcu. Vivamus rutrum consectetur urna nec luctus. Vivamus nibh mauris, maximus at mi ac, rutrum faucibus tellus. Nam blandit urna et condimentum consectetur.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur at ex mauris. Vestibulum vulputate condimentum purus id dapibus. Fusce elementum tempor augue, eget tincidunt tortor posuere id. Vestibulum eu diam egestas, aliquam eros ac, pellentesque arcu. Donec vel nibh non lorem semper elementum. Proin cursus, mi et sodales ornare, arcu tellus pellentesque mauris, ut tempus magna ligula malesuada metus. Proin eget malesuada est. Curabitur sit amet leo ac quam cursus aliquet. Nunc vitae porttitor nisi. Cras vitae nulla id augue efficitur interdum. Quisque tempus ligula quis nibh lobortis, eu maximus orci dictum. Nulla a diam eget ex vestibulum rhoncus.

Suspendisse feugiat neque sit amet faucibus facilisis. Praesent nec sapien id odio ultrices lacinia vel ut lectus. Sed scelerisque luctus nisi eu luctus. Quisque a lorem eget ipsum venenatis ultricies quis ut velit. Suspendisse et auctor tellus. Fusce mauris lectus, semper in nisl sit amet, fringilla mollis odio. Praesent rhoncus, dui eget sodales fringilla, lectus ligula accumsan mauris, a malesuada lectus enim non tortor. Curabitur tincidunt, lacus ac condimentum vulputate, libero est vulputate enim, consequat tincidunt risus nunc quis arcu. Vivamus rutrum consectetur urna nec luctus. Vivamus nibh mauris, maximus at mi ac, rutrum faucibus tellus. Nam blandit urna et condimentum consectetur.

Dr. Arsenault is a family medicine practitioner and pain management expert and an associate professor of family medicine at Université de Sherbrooke. He has vast experience in clinical research and is a Clinical Physician Investigator (CPI) at DIEX Research.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur at ex mauris. Vestibulum vulputate condimentum purus id dapibus. Fusce elementum tempor augue, eget tincidunt tortor posuere id. Vestibulum eu diam egestas, aliquam eros ac, pellentesque arcu. Donec vel nibh non lorem semper elementum. Proin cursus, mi et sodales ornare, arcu tellus pellentesque mauris, ut tempus magna ligula malesuada metus. Proin eget malesuada est. Curabitur sit amet leo ac quam cursus aliquet. Nunc vitae porttitor nisi. Cras vitae nulla id augue efficitur interdum. Quisque tempus ligula quis nibh lobortis, eu maximus orci dictum. Nulla a diam eget ex vestibulum rhoncus.

Suspendisse feugiat neque sit amet faucibus facilisis. Praesent nec sapien id odio ultrices lacinia vel ut lectus. Sed scelerisque luctus nisi eu luctus. Quisque a lorem eget ipsum venenatis ultricies quis ut velit. Suspendisse et auctor tellus. Fusce mauris lectus, semper in nisl sit amet, fringilla mollis odio. Praesent rhoncus, dui eget sodales fringilla, lectus ligula accumsan mauris, a malesuada lectus enim non tortor. Curabitur tincidunt, lacus ac condimentum vulputate, libero est vulputate enim, consequat tincidunt risus nunc quis arcu. Vivamus rutrum consectetur urna nec luctus. Vivamus nibh mauris, maximus at mi ac, rutrum faucibus tellus. Nam blandit urna et condimentum consectetur.